New hope for young transplant patients: drug combo may prevent deadly immune attack
NCT ID NCT06995521
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This study tests whether adding the drug vorinostat to standard medications can prevent graft-versus-host disease (GVHD) in children and young adults (ages 1-26) with non-cancerous blood or immune disorders who receive a bone marrow transplant. About 55 participants will receive vorinostat along with either tacrolimus and methotrexate or post-transplant cyclophosphamide, tacrolimus, and mycophenolate. The goal is to improve survival without severe GVHD or graft failure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.